Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Parasitic organism or component thereof or substance...
Patent
1973-03-19
1978-08-29
Schenkman, Leonard
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Parasitic organism or component thereof or substance...
A61K 31415
Patent
active
041104617
ABSTRACT:
A therapeutic method of alleviating the symptoms and relieving intraocular pressure associated with open or wide-angle glaucoma which comprises administering a compound selected from diphenylhydantoin (DPH), mephenytoin, and ethotoin in an amount ranging from 200-900 mg per day preferably on a split or divided dosage basis for a period of 2-5 months. A preferred regimen for DPH is 100 mg three times per day.
REFERENCES:
physicians Desk Reference, PDR, (1971) 25th Edition, p. 1003.
Cutting, Handbook of Pharmacology, 1969, pp. 669-671.
Becker et al., J. Clin. Endocrinol. Metab., vol. 32, No. 5, pp. 669-670 (1971).
Asseff Carl F.
Becker Bernard
Podos Steven M.
Stamper Robert L.
Ferris Thomas G.
Latker Norman J.
Roberts, Jr. John S.
Schenkman Leonard
The United States of America as represented by the Department of
LandOfFree
Effect of diphenylhydantoin and related compounds on glaucoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Effect of diphenylhydantoin and related compounds on glaucoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Effect of diphenylhydantoin and related compounds on glaucoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1633586